Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions
Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions作者机构：Oncology Institute of Wuxi the Fourth Affiliated Hospital of Soochow University Wuxi 214062 Jiangsu Province China College of life sciences Zhejiang University Hangzhou 310012 Zhejiang Province China
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2007年第13卷第6期
页 面：950-954页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：grant from Scientific and Technologic Bureau of Wuxi No. CS055010
主 题：Colorectal cancer Methylation Feces Secreted frizzled-related protein gene 2 Hyperplastic polyposis protein gene Methylguanine-DNA methyltransferase gene
摘 要：AIM： To investigate the feasibility of detecting methylated fecal DNA as a screening tool for colorectal carcinoma （CRC） and precancerous lesions. METHODS： Methylated secreted frizzled-related protein gene 2 （SFRP2）, hyperplastic polyposis protein gene （HPP1） and O6-methylguanine-DNA methyltransferase gene （MGMT） in stools from 52 patients with CRC, 35 patients with benign colorectal diseases and 24 normal individuals were analyzed using methylation-specific PCR. RESULTS： Methylated SFRP2, HPP1 and MGMT were detected in 94.2%, 71.2%, 48.1% of CRC patients and 52.4%, 57.1%, 28.6% of adenoma patients, respectively. The overall prevalence of fecal DNA with at least one methylated gene was 96.2% and 81.8% in patients with CRC and precancerous lesions, respectively. In contrast, only one of the 24 normal individuals revealed methylated DNA. These results indicated a 93.7% sensitivity and a 77.1% specificity of the assay for detecting CRC and precancerous lesions. CONCLUSION： IVlethylation testing of fecal DNA using a panel of epigenetic markers may be a simple and promising non-invasive screening method for CRC and precancerous lesions.
维普期刊数据库